- Home
- ULS vs BAX Comparison
ULS vs BAX Comparison
Compare ULS & BAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ULS | BAX |
|---|---|---|
| Founded | 1894 | 1931 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.5B | 13.9B |
| IPO Year | 2023 | 1994 |
Fundamental Metrics
Financial Performance| Metric | ULS | BAX |
|---|---|---|
| Price | $74.43 | $24.58 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 13 | 14 |
| Target Price | ★ $96.57 | $27.92 |
| AVG Volume (30 Days) | 1.1M | ★ 6.1M |
| Earning Date | 11-03-2026 | 10-29-2026 |
| Dividend Yield | ★ 0.79% | 0.16% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.66 | 0.21 |
| Revenue | $3,053,000,000.00 | ★ $11,244,000,000.00 |
| Revenue This Year | $5.47 | $3.33 |
| Revenue Next Year | $7.58 | $2.13 |
| P/E Ratio | ★ $44.05 | $116.45 |
| Revenue Growth | ★ 6.38 | 5.72 |
| 52 Week Low | $63.17 | $15.73 |
| 52 Week High | $107.54 | $30.00 |
Technical Indicators
Market Signals| Indicator | ULS | BAX |
|---|---|---|
| Relative Strength Index (RSI) | 63.87 | 52.33 |
| Support Level | $68.50 | $21.28 |
| Resistance Level | $76.19 | $30.00 |
| Average True Range (ATR) | 2.03 | 0.70 |
| MACD | 0.93 | 0.11 |
| Stochastic Oscillator | 93.00 | 53.82 |
Price Performance
Historical ComparisonAbout ULS UL Solutions Inc.
UL Solutions is a global leader specializing in a broad range of product testing, inspection, and certification services. UL Solutions is the for-profit branch out of three organizations under the UL Enterprise. TIC operations make up nearly all of UL Solutions' total revenue and are composed of two segments: industrial and consumer. UL Solutions' remaining business includes software and advisory, which complements its core TIC offerings. The firm operates globally.
About BAX Baxter International Inc.
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.